NCT02839681 2019-05-21Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung AdenocarcinomaNational Institutes of Health Clinical Center (CC)Phase 2 Terminated2 enrolled 12 charts